BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.

doi:10.1097/JTO.0b013e31827db621

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2013

Karachaliou Niki, Costa Carlota, Gimenez-Capitan Ana, Molina-Vila Miguel Angel, Bertran-Alamillo Jordi, Mayo Clara, Massuti Bartomeu, Majem Margarita, Carcereny Enric, Moran Teresa, Sanchez Jose Javier, Viteri Santiago, Gasco Amaya, Wannesson Luciano, Souglakos John, Jimeno Jose, Rosell Rafael

Abstract excerpt

INTRODUCTION: Lung adenocarcinoma patients harboring EGFR activating mutations attain improved progression-free survival (PFS) with treatment with epidermal growth factor receptor tyrosine kinase inhibitors. However, patients ultimately relapse, indicating that other genetic factors could influence outcome in such patients. We hypothesized that PFS could be influenced by the expression of genes in DNA repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Bronchiolo-Alveolar

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Carcinoma, Large Cell

Share to Endodeoxyribonucleases

Share to Erlotinib Hydrochloride

Share to LIM Domain Proteins

Share to Quinazolines

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 23407556
DOI: 10.1097/JTO.0b013e31827db621

Genes

LMO4
BRCA1
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.PMID 23407556Read ↗

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.Semantic proximity Read ↗

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancerSemantic proximity Read ↗

Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 ActivitySemantic proximity Read ↗

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.Semantic proximity Read ↗

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.